Global Oncology Academy - Global Oncology Academy

Global Oncology Academy

Global Oncology Academy

Enhance your practice with CME
and tools that focus on the management
and treatment of patients with cancer.

Popular

Exploring Sub-Ablative Radiation to Modulate Immunity in Mesothelioma
Exploring Sub-Ablative Radiation to Modulate Immunity in Mesothelioma
Project Oncology®
Exploring Sub-Ablative Radiation to Modulate Immunity in Mesothelioma
John Cho, MD, PhD, FRCPC
- John Cho, MD, PhD, FRCPC
How Novel Strategies Could Push ALK+ mNSCLC Care Forward
How Novel Strategies Could Push ALK+ mNSCLC Care Forward
Project Oncology®
How Novel Strategies Could Push ALK+ mNSCLC Care Forward
Angel Qin, MD
- Angel Qin, MD
Guiding mNSCLC Treatment After ALK-TKI Progression
Guiding mNSCLC Treatment After ALK-TKI Progression
Project Oncology®
Guiding mNSCLC Treatment After ALK-TKI Progression
Alice T. Shaw, MD, PhD
- Alice T. Shaw, MD, PhD
Investigating Unanswered Questions in ALK+ mNSCLC Care
Investigating Unanswered Questions in ALK+ mNSCLC Care
Project Oncology®
Investigating Unanswered Questions in ALK+ mNSCLC Care
Alice T. Shaw, MD, PhD
- Alice T. Shaw, MD, PhD
Comparing CAR T-Cell Therapies for R/R Multiple Myeloma
Comparing CAR T-Cell Therapies for R/R Multiple Myeloma
Project Oncology®
Comparing CAR T-Cell Therapies for R/R Multiple Myeloma
Charles Turck, PharmD, BCPS, BCCCP; Krina Patel, MD, MSc
- Charles Turck, PharmD, BCPS, BCCCP
- Krina Patel, MD, MSc
Updated Overall Survival From Stage 1 of PRESERVE-003: Gotistobart vs Docetaxel in Metastatic Squamous NSCLC After Anti-PD-(L)1 Progression
Updated Overall Survival From Stage 1 of PRESERVE-003: Gotistobart vs Docetaxel in Metastatic Squamous NSCLC After Anti-PD-(L)1 Progression
Oncology and Hematology
Updated Overall Survival From Stage 1 of PRESERVE-003: Gotistobart vs Docetaxel in Metastatic Squamous NSCLC After Anti-PD-(L)1 Progression
Byoung Chul Cho, MD, PhD
- Byoung Chul Cho, MD, PhD
Managing MAPK Inhibitor Adverse Events in Pediatric Low-Grade Gliomas
Managing MAPK Inhibitor Adverse Events in Pediatric Low-Grade Gliomas
Project Oncology®
Managing MAPK Inhibitor Adverse Events in Pediatric Low-Grade Gliomas
Alexandria May, PharmD, BCPS; Shannon Raber, MS, CPNP, RN
- Alexandria May, PharmD, BCPS
- Shannon Raber, MS, CPNP, RN
- Bridget Archambault, MSN, CPNP
The Evolving Role of Antibody-Drug Conjugates in NSCLC Care
The Evolving Role of Antibody-Drug Conjugates in NSCLC Care
Project Oncology®
The Evolving Role of Antibody-Drug Conjugates in NSCLC Care
Raghava Reddy Induru, MD
- Raghava Reddy Induru, MD

Medical News

Medical News
MFBG PET Improves Baseline Staging in Neuroblastoma
10/06/2026
Read more
Medical News
Predictors of Early Relief After Cancer-Related Pain Procedures
09/29/2026
Read more
Medical News
Medicare Part D Anticancer Drug Appeals Overturned 1 in 5 Times
09/28/2026
Read more
Medical News
Stepped Reminders Boost Lung Cancer Screening Adherence
09/17/2026
Read more

CME/CE

CME/CE In-Person & Virtual Event
Spotlight on B7-H3 ES-SCLC: Applying ADC Evidence in Real-World Practice
December 5, 2026
Scottsdale, Arizona
1.00 credit
Redefining Endocrine Therapy: The Evidence Behind Oral SERDs and PROTAC ER Degraders
Redefining Endocrine Therapy: The Evidence Behind Oral SERDs and PROTAC ER Degraders
MinuteCE®
Redefining Endocrine Therapy: The Evidence Behind Oral SERDs and PROTAC ER Degraders
Komal Jhaveri, MD, FACP
0.50 program credits
- Komal Jhaveri, MD, FACP
0.50 program credits
The Sequencing Puzzle: Integrating Oral SERDs and PROTACs into the mBC Treatment Landscape
The Sequencing Puzzle: Integrating Oral SERDs and PROTACs into the mBC Treatment Landscape
MinuteCE®
The Sequencing Puzzle: Integrating Oral SERDs and PROTACs into the mBC Treatment Landscape
Komal Jhaveri, MD, FACP; Virginia Kaklamani, MD, DSc
0.50 program credits
- Komal Jhaveri, MD, FACP
- Virginia Kaklamani, MD, DSc
0.50 program credits
Clinical Evidence for Anti-CD38–Based Frontline Regimens in Transplant-Eligible Patients With Multiple Myeloma
Clinical Evidence for Anti-CD38–Based Frontline Regimens in Transplant-Eligible Patients With Multiple Myeloma
MinuteCE®
Clinical Evidence for Anti-CD38–Based Frontline Regimens in Transplant-Eligible Patients With Multiple Myeloma
Natalie S. Callander, MD
0.75 program credits
- Natalie S. Callander, MD
0.75 program credits

Clinical Practice

From Durability to Discovery: Advances in ALK+ mNSCLC Treatment
From Durability to Discovery: Advances in ALK+ mNSCLC Treatment
Project Oncology®
From Durability to Discovery: Advances in ALK+ mNSCLC Treatment
Angel Qin, MD
- Angel Qin, MD
How ALK Vaccines Could Prolong TKI Response in mNSCLC
How ALK Vaccines Could Prolong TKI Response in mNSCLC
Project Oncology®
How ALK Vaccines Could Prolong TKI Response in mNSCLC
Angel Qin, MD
- Angel Qin, MD
Interpreting Oral SERD Trial Data in Metastatic Breast Cancer
Interpreting Oral SERD Trial Data in Metastatic Breast Cancer
On the Frontlines of Metastatic Breast Cancer
Interpreting Oral SERD Trial Data in Metastatic Breast Cancer
Alexandria May, PharmD, BCPS; Donald McDonnell, PhD
- Alexandria May, PharmD, BCPS
- Donald McDonnell, PhD
- Neil M. Iyengar, MD
A New Era of Hope in Non-Small Cell Lung Cancer Care
A New Era of Hope in Non-Small Cell Lung Cancer Care
Project Oncology®
A New Era of Hope in Non-Small Cell Lung Cancer Care
Geoffrey Oxnard, MD
- Geoffrey Oxnard, MD

Programs

Patterns of Progression and Resistance in ALK+ mNSCLC
Patterns of Progression and Resistance in ALK+ mNSCLC
Project Oncology®
Patterns of Progression and Resistance in ALK+ mNSCLC
Alice T. Shaw, MD, PhD
- Alice T. Shaw, MD, PhD
Antibody-Drug Conjugates for NSCLC: How They Work and Who’s a Candidate
Antibody-Drug Conjugates for NSCLC: How They Work and Who’s a Candidate
Project Oncology®
Antibody-Drug Conjugates for NSCLC: How They Work and Who’s a Candidate
Laura Alder, MD
- Laura Alder, MD
A Patient-First Approach to Smoking Cessation and Lung Cancer Screening
A Patient-First Approach to Smoking Cessation and Lung Cancer Screening
Project Oncology®
A Patient-First Approach to Smoking Cessation and Lung Cancer Screening
Lisa Carter-Bawa, PhD, MPH, APRN, ANP-C, FAAN, FSBM
- Lisa Carter-Bawa, PhD, MPH, APRN, ANP-C, FAAN, FSBM
Why Molecular Testing Matters in Non-Small Cell Lung Cancer
Why Molecular Testing Matters in Non-Small Cell Lung Cancer
Project Oncology®
Why Molecular Testing Matters in Non-Small Cell Lung Cancer
Geoffrey Oxnard, MD
- Geoffrey Oxnard, MD